NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
The Protrieve PROTECTOR Study
The Protrieve PROTECTOR Study
CompletedNA
Sponsor: Inari Medical
Conditions: Venous Thromboembolism, Deep Venous Thrombosis
Interventions: Percutaneous mechanical thrombectomy (PMT)
Countries: United States
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Eligibility overview
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: INTERVENTIONAL
Eligibility criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE: 1. Bilateral iliofemoral DVT 2. Clot extending into or located in the IVC 3. In-stent thrombosis 4. Presence of thrombosed IVC filter 5. Other features that the investigator deems put the subject at elevated risk for thromboembolism 3. Willing and able to provide informed consent Exclusion Criteria: 1. Current symptomatic PE 2. Known anatomic inability to place Protrieve device via jugular vein access site 3. Presence of clot extending to the IVC-Right Atrial junction or in the SVC 4. Subject is pregnant 5. Severe allergy to iodinated contrast agents that cannot be mitigated 6. INR \> 1.7 if not currently on anticoagulation therapy, platelets \< 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin \< 8.0 g/dL 7. Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents 8. Subject is participating in another study that may interfere with this study 9. Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject 10. Subject has previously completed or withdrawn from this study 11. Limb-threatening circulatory compromise (e.g., phlegmasia) 12. Uncontrolled severe hypertension on repeated readings (systolic \> 180mmHg or diastolic \> 105mmHg) 13. Severe allergy, hypersensitivity to, or thrombocytopenia from heparin 14. Inability to provide therapeutic anticoagulation per Investigator discretion 15. Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period 16. Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Locations (15)
- Newport Beach, California, United States
- New Haven, Connecticut, United States
- Miami, Florida, United States
- Indianapolis, Indiana, United States
- Baltimore, Maryland, United States
- Boston, Massachusetts, United States
- Las Vegas, Nevada, United States
- Englewood, New Jersey, United States
- New York, New York, United States
- Philadelphia, Pennsylvania, United States
- Pittsburgh, Pennsylvania, United States
- Nashville, Tennessee, United States
- Galveston, Texas, United States
- Houston, Texas, United States
- Morgantown, West Virginia, United States